{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibbekyffe63suxm2a7ml65viknj7pft57qjep6nvecka7em4cevd4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mnqhh5jqfz62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreie6vydqrex2tpxdlvqfghmnqz7nm6yzih2czze67hq3ypyr6mdwzy"
    },
    "mimeType": "image/jpeg",
    "size": 307415
  },
  "path": "/news/2026-06-weight-loss-treatments-linked-obesity.html",
  "publishedAt": "2026-06-07T19:10:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers. The research found that GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide (brand names: Ozempic, Wegovy) and tirzepatide (brand names: Mounjaro and Zepbound), were associated with a 41% decrease in the overall risk of developing cancer among non-diabetic patients who used the drugs for weight management, compared to those who relied on diet and exercise alone.",
  "title": "Weight loss treatments linked to lower risk of obesity-related cancers in people without diabetes"
}